

Determinazione del Direttore della SSD Formazione n° 138 del 01.02.2019

Oggetto: Aggiornamento obbligatorio, Infermiere, Dott. Francesca Maria Onidi.

PDTD/2019/137

Publicata all'Albo Pretorio dell'Azienda Ospedaliera a partire dal 01.02.2019 per 15 giorni consecutivi e posta a disposizione per la consultazione.

Il Responsabile della SSD Formazione

- Visto** il D. Lgs. n. 502/92 e successive modificazioni ed integrazioni;
- Viste** le Leggi Regionali n. 10/2006 e n. 05/2007;
- Vista** la Deliberazione n. 263 del 04.03.2015, con la quale il commissario Straordinario ha autorizzato il Direttore della SSD Formazione Dott. Andrea Corrias, a predisporre le Determinazioni;
- Vista** la comunicazione Prot. n° 813 del 25/01/2019, con la quale il Direttore S.C. Gastroenterologia ha fatto richiesta di comando obbligatorio per aggiornamento, in favore dell' Infermiere Dott. Francesca Maria Onidi;
- Ritenuto** di dover autorizzare la partecipazione dell'Infermiere Dott. Francesca Maria Onidi al Congresso "ECCO '19 Copenhagen Congress; European Crohn's and Colitis Organisation" che si terrà a Copenhagen dal 06/03/2019 al 09/03/2019, per un importo presunto complessivo di € 1.295,00 (milleduecentonovantacinque euro) come da documentazione allegata per farne parte integrale e sostanziale;
- Considerato** che tale spesa ricadrà sul Fondo per l'aggiornamento obbligatorio del Comparto – Dipartimento Oncologico-Internistico - fondi di struttura anno 2019, di cui risulta verificata la copertura finanziaria e che la liquidazione dei costi sostenuti dovrà essere effettuata previa trasmissione a cura dell' Infermiere Dott. Francesca Maria Onidi ai competenti Uffici della documentazione giustificativa, di una relazione sull'aggiornamento e dell'Attestato di partecipazione al Congresso ;

Segue determinazione n. 138 del 01.02.2019

D E T E R M I N A

Per i motivi esposti in premessa:

1. Autorizzare la partecipazione dell'Infermiere Dott. Francesca Maria Onidi al Congresso "ECCO '19 Copenhagen Congress; European Crohn's and Colitis Organisation" che si terrà a Copenhagen dal 06/03/2019 al 09/03/2019.
2. Autorizzare dell'Infermiere Dott. Francesca Maria Onidi a partire il giorno precedente all'inizio del Corso per motivi organizzativi.
3. Dare atto che l'importo complessivo presunto di € 1.295,00 (milleduecentonovantacinque euro) ricadrà sul Fondo per l'aggiornamento obbligatorio del Comparto – Dipartimento Oncologico-Internistico - fondi di struttura anno 2019, di cui risulta verificata la copertura finanziaria.
4. Disporre che la liquidazione dei costi sostenuti dall'Infermiere Dott. Francesca Maria Onidi venga effettuata previa trasmissione ai competenti Uffici della documentazione giustificativa, di una relazione sull'aggiornamento e dell'Attestato di partecipazione al Congresso .
5. Trasmettere la presente determinazione al Direttore della S.C. Gestione Sviluppo Risorse Umane.

Il Direttore della SSD Formazione
Dott. Andrea Corrias



Emissione 28/01/2018
Revisione 02/05/2018

Richiesta di Aggiornamento Obbligatorio
Fuori sede

MO-DG-FOR-017.2
Pagina 1 di 4

LA DOMANDA DEVE ESSERE COMPILATA IN OGNI SUA PARTE E PRESENTATA DAL RICHIEDENTE ALMENO 15 GIORNI PRIMA DELLA DATA D'INIZIO DELL'ATTIVITA' FORMATIVA

N. protocollo NP 2019/1813 25.1.19

1. Si richiede di autorizzare il dipendente

Nome e Cognome FRANCESCA MARIA ONIDI

Struttura di appartenenza GASTROENTEROLOGIA

Dipartimento INTERISTICO

Telefono /cellulare francesca.onidi@aoibrotzu.it

Qualifica INFERTIERA

Area contrattuale:

- Comparto
- Dirigenza Sanitaria
- Dirigenza Medica
- Dirigenza Tecnica – Amministrativa – Profes.

Contratto a tempo determinato a tempo indeterminato

Data (gg/mm/aaaa) 15/01/2019

Nome e cognome del partecipante per assenso

Firma (leggibile) Francesca Onidi

2. Parere del sovraordinato gerarchico per il personale del comparto

Parere di congruità e compatibilità alle esigenze di servizio:

Favorevole Non favorevole

Motivazione del parere: _____

Firma e Timbro (leggibile) Del Coordinatore per il comparto sanità Marco Collu
AO Brotzu - Cagliari
S.C. GASTROENTEROLOGIA
COORDINATORE
MARCO COLLU

Fondo:

- fondo di struttura
- fondo strategico Aziendale (vedi punto 5)
- fondo vincolato (specificare denominazione del fondo e allegare resoconto fondo a cura del settore economico)

Data (gg/mm/aaaa): 15/01/2019

Firma e Timbro (leggibile)

Il Direttore di Struttura

Firma e Timbro (leggibile)

Il Direttore di Dipartimento

AO Brotzu - Cagliari

DIPARTIMENTO ONCOLOGICO INTERNISTICO

Direttore Dott. Roberto Ganga

Azienda Ospedaliera Brotzu
P.le Ricchi, 1 - 09134 – Cagliari
P.iva: 02315520920
www.aobrotzu.it

Ufficio Formazione
Responsabile: Dott. Andrea Corrias
Tel. 070.5296.5576
Tel. 070.5296.5575-5578-5574
Fax: 070.5296.5594
E-mail: ufficioformazione@aob.it

AO Brotzu
Sede Ufficio Formazione
Corpo G 1° piano
Via Edward Jenner
09121 Cagliari
www.aob.it

AZIENDA OSPEDALIERA "G. BROTZU" CAGLIARI
S.C. GASTROENTEROLOGIA
Direttore Dott. Francesco Corrias

**3. Dati dell'attività formativa**Titolo: Ecco '19 Copenhagen CONGRESS, EUROPEAN CROHN'S AND COLITIS ORGANISATIONSede: COPENHAGEN

Data:	da (gg/mm/aaaa) <u>6/3/19</u>	a (gg/mm/aaaa) <u>9/3/19</u>	Durata dell'attività formativa in ore: N. _____
Tipologia evento			
<input type="checkbox"/> Corso <input type="checkbox"/> corso teorico/pratico <input checked="" type="checkbox"/> Congresso <input type="checkbox"/> Convegno <input type="checkbox"/> Seminario <input type="checkbox"/> frequenza in altra struttura			
Organizzatore:			

Se organizzatore esterno, indicare il C.F./P.IVA/n. provider OCEAIN, GmbHAttività ECM? Sì | No Se sì, indicare il numero di crediti ECM assegnati: 6Allega* il programma e le notizie sui contenuti e gli scopi formativi: Sì | No**Diversamente NON SARÀ POSSIBILE AUTORIZZARE E RIMBORSARE L'AGGIORNAMENTO INDIVIDUALE.***4. Preventivo di spesa**

Ipotesi di spesa totale:

<ul style="list-style-type: none"> Se prevista Iscrizione il dipendente deve informare la segreteria scientifica che la quota deve essere esente IVA: <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Anticipata dal dipendente (la fattura deve essere intestata al dipendente) <input type="checkbox"/> A carico e fatturata direttamente all'AOb compilare il campo 7. Esenzione IVA <input type="checkbox"/> Non prevista 	€ 205,00
• Vitto:	€ 100,00
• Pernottamento:	€ 260,00
<ul style="list-style-type: none"> Viaggio: <ul style="list-style-type: none"> *Partenza giorno prima <input checked="" type="checkbox"/> *Rientro giorno dopo <input type="checkbox"/> 	€ 730,00
• Altre spese:	€
Totale spesa presunta	€ <u>1.295,00</u>

** il dipendente chiede sotto la propria responsabilità di essere autorizzato, per motivi legati ai trasporti, alla partenza il giorno prima e/o al rientro il giorno dopo l'evento.***ATTENZIONE:** non potranno essere rimborsate spese sostenute senza la consegna delle pezze giustificative in originale

Emissione 28/01/2018
Revisione 02/05/2018Richiesta di Aggiornamento Obbligatorio
Fuori sedeMO-DG-FOR-017.2
Pagina 4 di 4**7. Esenzione IVA***(Da inviare alla Segreteria Organizzativa a cura del dipendente)*

Alla Segreteria Organizzativa

Oggetto: Partecipazione al corso di aggiornamento obbligatorio

Del dipendente ONIDA FRANCESCA MARIA

Si comunica che il dipendente di questa Azienda Ospedaliera Brotzu

è stata/o autorizzata/o a partecipare in regime di aggiornamento obbligatorio alla frequenza del:

Corso corso teorico/pratico Congresso Convegno Seminario frequenza in altra strutturaTitolo: ECCO'19 COPENHAGEN CONGRESS, EUROPEAN CARDIAC MEDICAL SOCIETYSede: COPENHAGENData: da (gg/mm/aaaa) 5/3/2019 a (gg/mm/aaaa) 9/3/2019

Si chiede pertanto che la fatturazione (fattura non quietanzata) della quota d'iscrizione sia intestata all'Azienda Ospedaliera G. Brotzu, P.le Ricchi 1, 09134 Cagliari – P. IVA 02315520920 e sia emessa senza l'imposta sul valore aggiunto in base al DPR 633/72 e alla L. 537/93 art. 14 comma 10.

Codice univoco FIEFE2

Data, 20.1.2019Firma e Timbro (leggibile)
Il Direttore SSD Formazione

AO Brotzu - Cagliari
SSD FORMAZIONE
Resp.: Dott. Andrea Corrias



Emissione 28/01/2018
Revisione 02/05/2018

Richiesta di Aggiornamento Obbligatorio
Fuori sede

MO-DG-FOR-017.2
Pagina 3 di 4

5. Parere del Responsabile della Direzione Aziendale

(Utilizzare questo campo solo Se richiesto utilizzo del Fondo Strategico Aziendale)

 Favorevole Non favorevole

Motivazione del parere:

Firma e Timbro (leggibile)

Il Direttore Generale (o suo delegato)

Luogo: _____


Data (gg/mm/aaaa): _____

6. Parere del Responsabile SSD Formazione

Verifica e Parere di fattibilità per competenze dell'Ufficio:


 Favorevole Non favorevole

Motivazione del parere:



Data, 28-1-2019

Firma e Timbro (leggibile)
Il Direttore SSD Formazione


AO Brotzu - Cagliari
SSD FORMAZIONE
Resp. Dott. Andrea Corrias



European
Crohn's and Colitis
Organisation

Our Congress (<https://www.ecco-ibd.eu/ecco19.html>) Discover the Programme (</discover-the-programme-2019.html>)
Register (</register-2019.html>) Abstracts (</abstracts-2019.html>) Exhibit & Sponsor (</exhibit-sponsor-2019.html>)
Network (</network-2019.html>) Hotels (</hotels-2019.html>) Explore Copenhagen (</explore-copenhagen.html>)

1st Guideline Methodology and GRADE Workshop

//c

DATE	March 7, 2019
TIME	Thursday, March 7 from 08:00 to 12:00
ORGANISATION	GuiCom
TARGET AUDIENCE	All health care professionals who are interested in guidelines and guideline development
REGISTRATION	Register now!
ECCO MEMBERSHIP	Regular/Y-ECCO/IBD Nurse/Affiliate Membership 2019
REGISTRATION FEE	EUR 50.- incl. 25% Danish VAT Kindly direct any question or further clarification to the ECCO Office at ecco19@ecco-ibd.eu (mailto:ecco19@ecco-ibd.eu)
CME ACCREDITATION	3 CME credits

Thursday, March 7, 2019

1st Guideline Methodology and GRADE Workshop (as of December 2018)		
08:00-10:15	Session 1 Gionata Florino, Milan, Italy Joana Torres, Lisbon, Portugal	
	08:00-08:15	1: Welcome & Introduction Gionata Florino, Milan, Italy
	08:15-09:45	2: What you need to know to understand the GRADE methodology Stefanos Bonovas, Milan, Italy
	09:45-10:05	3: Patient perspectives of guidelines - why should patients be involved Clara Drohan, Dublin, Ireland (EFCCA patient representative) Evelyn Groß, Graz, Austria (EFCCA patient representative) Sanna Lönnfors, Pyhtää, Finland (EFCCA patient representative) Marko Perovic, Belgrade, Serbia (EFCCA patient representative)
	10:05-10:15	4: What is the role of patients in the GRADE methodology Stefanos Bonovas, Milan, Italy
10:15-10:45	Coffee break	
10:45-12:00	Session 2 Gionata Florino, Milan, Italy Tim Raine, Cambridge, United Kingdom	
	10:45-11:00	5: How to perform a scientifically sound literature research - the new ECCO SOP Joana Torres, Lisbon, Portugal
	11:00-11:45	6: The pros and cons of using the GRADE vs. Oxford methodology Tandem Talk: Marien González Lorenzo, Milan, Italy Theodore Lytras, Athens, Greece
	11:45-12:00	7: Discussion and conclusion Gionata Florino, Milan, Italy Joana Torres, Lisbon, Portugal

OUR CONGRESS

(<https://www.ecco-ibd.eu/ecco19.html>)

DISCOVER THE PROGRAMME

(</discover-the-programme-2019.html>)

Scientific Programme

(</discover-the-programme-2019/scientific-programme-2019.html>)

Educational Programme

1st ECCO-ESGAR Basic Imaging Workshop
(</discover-the-programme-2019/educational-programme-2019/1st-ecco-esgar-basic-imaging-workshop.html>)

1st Guideline Methodology and GRADE Workshop

(</discover-the-programme-2019/educational-programme-2019/1st-guideline-methodology-and-grade-workshop.html>)

3rd School for Clinical Trialists

(</discover-the-programme-2019/educational-programme-2019/3rd-school-for-clinical-trialists.html>)

4th Advanced ECCO: Educational COurse for Industry

(</discover-the-programme-2019/educational-programme-2019/4th-advanced-ecco-educational-course-for-industry.html>)

4th D-ECCO Workshop

(</discover-the-programme-2019/educational-programme-2019/4th-d-ecco-workshop.html>)

4th ECCO-AOCC Forum

(</discover-the-programme-2019/educational-programme-2019/4th-ecco-aocc-forum.html>)

4th H-ECCO IBD Masterclass

(</discover-the-programme-2019/educational-programme-2019/4th-h-ecco-ibd-masterclass.html>)

5th Y-ECCO Basic Science Workshop

(</discover-the-programme-2019/educational-programme-2019/5th-y-ecco-basic-science-workshop.html>)

6th ECCO-ESGAR Ultrasound Workshop - Advanced

(</discover-the-programme-2019/educational-programme-2019/6th-ecco-esgar-ultrasound-workshop.html>)

6th P-ECCO Educational Course



**European
Crohn's and Colitis
Organisation**

Our Congress (<https://www.ecco-ibd.eu/ecco19.html>) Discover the Programme (</discover-the-programme-2019.html>)
 Register (</register-2019.html>) Abstracts (</abstracts-2019.html>) Exhibit & Sponsor (</exhibit-sponsor-2019.html>)
 Network (</network-2019.html>) Hotels (</hotels-2019.html>) Explore Copenhagen (</explore-copenhagen.html>)

3rd School for Clinical Trialists

//c

DATE	March 6, 2019
TIME	Wednesday, March 6 from 08:00 to 11:30
ORGANISATION	ClinCom
TARGET AUDIENCE	Clinical trial coordinators, IBD nurses and Allied health professionals
REGISTRATION	Register now!
ECCO MEMBERSHIP	Regular/Y-ECCO/IBD Nurse/Affiliate Membership
REGISTRATION FEE	EUR 50.- incl. 25% Danish VAT Kindly direct any question or further clarification to the ECCO Office at ecco19@ecco-ibd.eu (mailto:ecco19@ecco-ibd.eu)
CME ACCREDITATION	3 CME credits

Wednesday, March 06, 2019

3rd School for Clinical Trialists: Clinical Trial Evolution and Recruitment in IBD (as of November 2018)	
08:00-08:15	1: Welcome & Introduction Marc Ferrante, Leuven, Belgium
08:15-09:30	Session 1: Evolution of trial design Javier Gisbert, Madrid, Spain
08:15-08:45	2: What did we achieve with the past IBD trials until now? Laurent Peyrin-Biroulet, Vandœuvre-lès-Nancy, France
08:45-09:15	3: What are the unmet needs and how can new type/innovative trials meet these? Gert van Assche, Leuven, Belgium
09:15-09:30	4: General Discussion
09:30-10:00	Coffee Break
10:00-11:20	Session 2: How to optimise recruitment Uri Kopylov, Tel Aviv, Israel
10:00-10:20	5: Clinical trial coordinator's view Martin Thomas, Cambridge, United Kingdom
10:20-10:40	6: Patient's view/IBD nurse's view (together) Carina Blixt, Hvidovre, Denmark Annette Munk Happel, Hvidovre, Denmark (IBD Patient)
10:40-11:00	7: PI's view Laurent Beaugerie, Paris, France
11:00-11:20	8: Group Discussion Laurent Beaugerie, Paris, France Carina Blixt, Hvidovre, Denmark Krisztina Gece, Amsterdam, The Netherlands Martin Thomas, Cambridge, United Kingdom Annette Munk Happel, Hvidovre, Denmark (IBD Patient) Wulf Böcher, Ingelheim, Germany (Boehringer Ingelheim)
11:20-11:30	9: Summary & Closing remarks John Mansfield, Newcastle upon Tyne, United Kingdom

OUR CONGRESS

(<https://www.ecco-ibd.eu/ecco19.html>)

DISCOVER THE PROGRAMME

(</discover-the-programme-2019.html>)

Scientific Programme

(</discover-the-programme-2019/scientific-programme-2019.html>)

Educational Programme

1st ECCO-ESGAR Basic Imaging Workshop
(</discover-the-programme-2019/educational-programme-2019/1st-ecco-esgar-basic-imaging-workshop.html>)
 1st Guideline Methodology and GRADE Workshop
(</discover-the-programme-2019/educational-programme-2019/1st-guideline-methodology-and-grade-workshop.html>)

3rd School for Clinical Trialists

(</discover-the-programme-2019/educational-programme-2019/3rd-school-for-clinical-trialists.html>)

4th Advanced ECCO: Educational Course for Industry

(</discover-the-programme-2019/educational-programme-2019/4th-advanced-ecco-educational-course-for-industry.html>)

4th D-ECCO Workshop

(</discover-the-programme-2019/educational-programme-2019/4th-d-ecco-workshop.html>)

4th ECCO-AOCC Forum

(</discover-the-programme-2019/educational-programme-2019/4th-ecco-aocc-forum.html>)

4th H-ECCO IBD Masterclass

(</discover-the-programme-2019/educational-programme-2019/4th-h-ecco-ibd-masterclass.html>)

5th Y-ECCO Basic Science Workshop

(</discover-the-programme-2019/educational-programme-2019/5th-y-ecco-basic-science-workshop.html>)

6th ECCO-ESGAR Ultrasound Workshop - Advanced

(</discover-the-programme-2019/educational-programme-2019/6th-ecco-esgar-ultrasound-workshop.html>)

6th P-ECCO Educational Course



European Crohn's and Colitis Organisation

- Our Congress (<https://www.ecco-ibd.eu/ecco19.html>) Discover the Programme (</discover-the-programme-2019.html>)
- Register (</register-2019.html>) Abstracts (</abstracts-2019.html>) Exhibit & Sponsor (</exhibit-sponsor-2019.html>)
- Network (</network-2019.html>) Hotels (</hotels-2019.html>) Explore Copenhagen (</explore-copenhagen.html>)

Scientific programme

//c

The scientific programme is structured around basic science, translational medicine and clinical sessions, given by some of the world's top specialists. It includes oral presentations of the best abstracts, the announcement of ECCO Fellowships and Grants and summary presentations of new ECCO Guidelines. The focus of all sessions is clinical practice founded on science, with practical messages to take home. Scientific sessions are held from Thursday to Saturday, March 7-9, 2019. The congress registration fee includes access to all scientific sessions.

Research drives clinical care
Preliminary programme (as of January 2019)

Thursday, March 7, 2019 Friday, March 8, 2019 Saturday, March 9, 2019

Plenary hall

07:15-08:15	Industry sponsored satellite symposia 3a, 3b, & 3c
08:30-10:30	Scientific session 4: Best practice in UC Andre D'Hoore, Leuven, Belgium Henit Yanai, Petah Tikva, Israel
08:30-08:50	20: When do you start a biologic? Simon Travis, Oxford, United Kingdom
08:50-09:00	21: OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with Moderately to Severely Active Ulcerative Colitis ¹ L. Peyrin-Biroulet, ² J. Panés, ³ M. Chloorean, ⁴ J. Zhang, ⁵ S. Vermeire, ⁶ V. Jairath, ⁷ A. Yarur, ⁸ C. Cabell, ⁹ S. Naik, ¹⁰ W. J. Sandborn ¹ University Hospital of Nancy, Vandœuvre-lès-Nancy, France, ² Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ³ Virginia Mason Medical Center, Seattle, United States, ⁴ Arena Pharmaceuticals, Inc., San Diego, United States, ⁵ University Hospitals Leuven, Leuven, Flanders, Belgium, ⁶ Western University, London, Ontario, Canada, ⁷ Medical College of Wisconsin, Milwaukee, United States, ⁸ University of California San Diego, La Jolla, United States
09:00-09:10	22: OP10: Systems genomics of Ulcerative Colitis: Combining GWAS and signalling networks for patient stratification and individualised drug targeting in Ulcerative Colitis ^{1,2} J. Brooks, ³ D. Modos, ⁴ P. Sudhakar, ⁵ D. Fazekas, ⁶ A. Zoufir, ⁷ A. Watson, ⁸ M. Tremelling, ⁹ B. Verstockt, ¹⁰ S. Vermeire, ¹¹ A. Bender, ¹² S. Carding, ¹³ T. Korcsmaros ¹ Norfolk and Norwich University Hospital, Gastroenterology, Norwich, United Kingdom, ² The Quadram Institute Bioscience, Gut Microbes and Health Programs, Norwich, United Kingdom, ³ Centre for Molecular Science Informatics, Department of Chemistry University of Cambridge, Cambridge, United Kingdom, ⁴ Earham Institute, Norwich Research Park, Norwich, United Kingdom, ⁵ KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, ⁶ Eötvös Loránd, Department of Genetics, Budapest, Hungary, ⁷ University of East Anglia, Norwich Medical School, Norwich, United Kingdom, ⁸ University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

OUR CONGRESS

(<https://www.ecco-ibd.eu/ecco19.html>)

DISCOVER THE PROGRAMME

(</discover-the-programme-2019.html>)

Scientific Programme

(</discover-the-programme-2019/scientific-programme-2019.html>)

Educational Programme

1st ECCO-ESGAR Basic Imaging Workshop

(</discover-the-programme-2019/educational-programme-2019/1st-ecco-esgar-basic-imaging-workshop.html>)

1st Guideline Methodology and GRADE Workshop

(</discover-the-programme-2019/educational-programme-2019/1st-guideline-methodology-and-grade-workshop.html>)

3rd School for Clinical Trialists

(</discover-the-programme-2019/educational-programme-2019/3rd-school-for-clinical-trialists.html>)

4th Advanced ECCO: Educational COurse for Industry

(</discover-the-programme-2019/educational-programme-2019/4th-advanced-ecco-educational-course-for-industry.html>)

4th D-ECCO Workshop

(</discover-the-programme-2019/educational-programme-2019/4th-d-ecco-workshop.html>)

4th ECCO-AOCC Forum

(</discover-the-programme-2019/educational-programme-2019/4th-ecco-aocc-forum.html>)

4th H-ECCO IBD Masterclass

(</discover-the-programme-2019/educational-programme-2019/4th-h-ecco-ibd-masterclass.html>)

5th Y-ECCO Basic Science Workshop

(</discover-the-programme-2019/educational-programme-2019/5th-y-ecco-basic-science-workshop.html>)

6th ECCO-ESGAR Ultrasound Workshop - Advanced

(</discover-the-programme-2019/educational-programme-2019/6th-ecco-esgar-ultrasound-workshop.html>)

6th P-ECCO Educational Course

09:10-09:20	<p>23: OP11: Organoids derived from inflamed intestinal biopsies of patients with Ulcerative Colitis lose their inflammatory phenotype during ex vivo culture</p> <p>^{1, 2} K. Arnauts, ^{1, 3} B. Verstockt, ¹ M. Vancamelbeke, ¹ S. Vermeire, ^{1, 3} C. Verfaillie, ^{1, 3, 1} M. Ferrante KU Leuven, Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), Leuven, Belgium, ³ KU Leuven, Department of Development and Regeneration, Leuven, Belgium, ³ KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium</p>
09:20-09:40	<p>24: Where is the exit?</p> <p>Marc Ferrante, Leuven, Belgium</p>
09:40-09:50	<p>25 OP12: Targeting inflammation in Ulcerative Colitis by inhibiting glucose uptake</p> <p>¹ R. Gropp, ¹ H. Jodeleit, ¹ J. Caesar, ¹ C. Villarroel Aguilera, ¹ F. Beigel, ^{2, 3} S. Breitenicher, ³ J. Stallhofer, ¹ M. Siebeck</p> <p>¹ Hospital of the Ludwig Maximilian University, General-, Visceral-, Vascular- and Transplantation Surgery, Munich, Germany, ² Hospital of the Ludwig Maximilian University, Laboratory Medicine, Munich, Germany, ³ Hospital of the Ludwig Maximilian University, Medicine II, Munich, Germany</p>
09:50-10:00	<p>26: OP13: Molecular response to ustekinumab in Moderate to Severe Ulcerative Colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study</p> <p>K. Li, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J. R. Friedman</p> <p>Janssen Research & Development, LLC, Spring House, United States</p>
10:00-10:10	<p>27: OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with Moderately to Severely Active Ulcerative Colitis: Data from the U-ACHIEVE study</p> <p>¹ W. J. Sandborn, ¹ S. Schreiber, ² S. D. Lee, ³ J. O. Lindsay, ⁴ X. Hebuterne, ⁵ W. Zhou, ⁶ F. Cataldi, ⁶ A. P. Lacerda, ⁶ B. Huang, ⁶ W. Xie, ⁶ E. V. Loftus Jr</p> <p>¹ University of California San Diego, ³ La Jolla, United States, ⁴ University Hospital Schleswig-Holstein, Kiel, Germany, ⁵ University of Washington, Seattle, United States, ⁶ Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁷ Service de Gastroentérologie et Nutrition Clinique, Nice, France; ⁸ Université de Nice-Sophia-Antipolis, Nice, France, ⁹ AbbVie Inc., North Chicago, United States, ¹⁰ Mayo Clinic, Rochester, United States</p>
10:10-10:30	<p>28: Precision surgery in UC</p> <p>Yves Panis, Clichy, France</p>
10:30-11:00	Coffee Break
11:00-12:30	<p>Scientific session 5: IBD around the world</p> <p>Toshifumi Hibi, Tokyo, Japan</p> <p>Giovanni Maconi, Milan, Italy</p>
11:00-11:20	<p>29: Vaccination and travelling with IBD: An update</p> <p>Jean-François Rahier, Yvoir, Belgium</p>

(/discover-the-programme-2019/educational-programme-2019/6th-p-ecco-educational-course.html)

7th SciCom Workshop: Mechanisms and therapeutic modulation of mucosal healing in IBD
(/discover-the-programme-2019/educational-programme-2019/7th-sci-com-workshop-mechanisms-and-therapeutic-modulation-of-mucosal-healing-in-ibd.html)

8th S-ECCO IBD Masterclass
(/discover-the-programme-2019/educational-programme-2019/8th-s-ecco-ibd-masterclass.html)

10th N-ECCO School
(/discover-the-programme-2019/educational-programme-2019/10th-n-ecco-school.html)

11th Y-ECCO Career Workshop
(/discover-the-programme-2019/educational-programme-2019/11th-y-ecco-career-workshop.html)

13th N-ECCO Network Meeting
(/discover-the-programme-2019/educational-programme-2019/13th-n-ecco-network-meeting.html)

17th IBD Intensive Advanced Course
(/discover-the-programme-2019/educational-programme-2019/17th-ibd-intensive-advanced-course.html)

Digital Oral Presentations
(/discover-the-programme-2019/digital-oral-presentation-2019.html)

- REGISTER
(/register-2019.html)
- ABSTRACTS
(/abstracts-2019.html)
- EXHIBIT & SPONSOR
(/exhibit-sponsor-2019.html)
- NETWORK
(/network-2019.html)
- HOTELS
(/hotels-2019.html)
- EXPLORE COPENHAGEN
(/explore-copenhagen.html)



(/index.php/component/zoo/item/eccologic-2-2.html)

	11:20-11:30	<p>30: OP15: Cost-analysis in a prospective European population-based inception cohort. Is there a cost-saving effect of biological therapy?</p> <p>J. Burisch¹, H. Vardi², D. Schwartz³, Z. Krznaric⁴, P. L. Lakatos⁵, M. Fumery⁶, L. Kupcinskas⁷, F. Magro⁸, E. Belousova⁹, P. Oksanen¹⁰, N. Arebi¹¹, E. Langholz¹², S. Turcan¹³, R. D'Inca¹⁴, V. Hernandez¹⁵, D. Valplani¹⁶, Z. Vegh¹⁷, M. Giannotta¹⁸, K. H. Katsanos¹⁹, D. Duricova²⁰, K. R. Nielsen²¹, H. A. L. Kievit²², P. Ellul²³, R. Salupere²⁴, A. Goldis²⁵, I. Kalmakliotis²⁶, N. Pedersen²⁷, V. Andersen²⁸, J. Halfvarson²⁹, S. Sebastian³⁰, J. F. Dahlerup³¹, P. Munkholm³², S. Odes³³, Epi-IBD³⁴</p> <p>North Zealand University Hospital, Frederikssund, Denmark, Ben Gurion University of the Negev, Beer Sheva, Israel, Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel, University Hospital Center Zagreb, Zagreb, Croatia, Semmelweis University, Budapest, Hungary, Amiens University and Hospital, Amiens, France, Lithuanian University of Health Sciences, Kaunas, Lithuania, Hospital de São João, Porto, Portugal, Moscow Regional Research Clinical Institute, Moscow, Russian Federation, Tampere University Hospital, Tampere, Finland, Imperial College London, London, United Kingdom, Herlev University Hospital, Herlev, Denmark, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Moldova, Republic of, Azienda Ospedaliera di Padova, Padova, Italy, Complexo Hospitalario Universitario de Vigo, Vigo, Spain, Morgagni Hospital, Forli, Italy, Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy, University Hospital, Ioannina, Greece, Charles University, Prague, Czech Republic, National Hospital of the Faroe Islands, Torshavn, Faroe Islands, Herning Hospital, Herning, Denmark, Mater Dei Hospital, Msida, Malta, Tartu University Hospital, Tartu, Estonia, University of Medicine 'Victor Babes', Timisoara, Romania, American Gastroenterology center, Nicosia, Cyprus, Slagelse Hospital, Department of medicine, Denmark, Regional Hospital of Viborg, Viborg, Denmark, Örebro University, Örebro, Sweden, Hull and East Yorkshire NHS Trust, Hull, United Kingdom, Aarhus University Hospital, Aarhus, Denmark</p>
	11:30-11:50	<p>31: Management of IBD outside of Europe: The example of India</p> <p>Rupa Banerjee, Hyderabad, India</p>
	11:50-12:00	<p>32: OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of Mild to Moderate Ulcerative Colitis: Efficacy results</p> <p>S. Bloom¹, T. Iqbal², C. Nwokolo³, M. Smith⁴, D. O'Donoghue⁵, J. Hall⁶, B. Dzyngel⁷</p> <p>University College London Hospitals, London, United Kingdom, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, University Hospital Coventry & Warwickshire, Coventry, United Kingdom, Shrewsbury and Telford Hospital, Shrewsbury, United Kingdom, St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, Sublimity Therapeutics, Solana Beach, United States</p>
	12:00-12:10	<p>33: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies</p> <p>R. Huang¹, H. Irizar², R. Kosoy³, W.-m. Song⁴, A. Dinarzo⁵, K. Hao⁶, J. Rogers⁷, A. Atreja⁸, M. Mahajan⁹, A. Stojmirovic¹⁰, J. Perrigoue¹¹, C. Brodmerkel¹², S. Plevy¹³, J. Friedman¹⁴, J.-F. Colombel¹⁵, M. Dubinsky¹⁶, B. Sands¹⁷, E. Schadt¹⁸, A. Kasarskis¹⁹, B. Losic²⁰, C. Argmann²¹, M. Suarez-Farinas²²</p> <p>Icahn School at Mount Sinai, Department of Population, Health Science and Policy, New York, United States, University College of London, London, United Kingdom, Icahn School at Mount Sinai, Department of Genetics and Genomic Science, New York, United States, Icahn School at Mount Sinai, Department of Medicine, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York City, United States, Janssen Research & Development, Janssen Biotech, Johnson & Johnson, Spring House, United States</p>
	12:10-12:30	<p>34: East meets West: Epidemiology of IBD</p> <p>Johan Burisch, Copenhagen, Denmark</p> <p>Siew Ng, Hong Kong, China</p>
	12:30-13:30	Break
	12:30-13:30	Guided poster session
	12:40-13:20	Educational Lunchtime Satellite Symposia LS1, LS2, LS3, & LS4
	13:30-14:40	<p>Scientific session 6: New ways of doing endoscopy and imaging in IBD</p> <p>Hankje Escher, Rotterdam, The Netherlands</p> <p>Christian Maaser, Lüneburg, Germany</p>

13:30-13:50	<p>35: Assessing bowel damage in CD from adult to childhood Anne Griffiths, Toronto, Canada</p>
13:50-14:00	<p>36: OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn's Disease: The paediatric Crohn's Disease adalimumab level-based optimisation treatment (PAILOT) trial A. Assa¹, M. Matar², D. Turner³, E. Broide⁴, B. Weiss⁵, O. Ledder⁶, A. Guz Mark², F. Rinawi¹, S. Cohen², C. Topf Olivestone³, R. Shaoul⁴, B. Yerushalmi⁵, R. Shamir¹ Schneider Children's Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, Schneider Children's medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, Shaare Zedek Medical Center, Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, Assaf Harofeh, Pediatric Gastroenterology, Zerifin, Israel, Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel, Shaare Zedek Medical Center, Pediatric Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, Tel Aviv Medical Center, Pediatric Gastroenterology, Tel-Aviv, Israel, Kaplan Medical Center, Pediatric Gastroenterology, Rehovot, Israel, Rambam Medical center, Pediatric Gastroenterology, Haifa, Israel, Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel</p>
14:00-14:20	<p>37: Best practice in screening for dysplasia Marietta Iacucci, Birmingham, United Kingdom</p>
14:20-14:30	<p>38: OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve Ulcerative Colitis Y. Haberman^{1,2}, R. Karns³, P. Dexheimer², M. Schirmer¹, T. Braun¹, M. Collins², A. Mo⁴, M. Rosen⁵, N. Gotman⁶, PROTECT Study group⁷, S. Kugathasan⁸, T. D. Walters⁹, G. Gibson¹⁰, S. Davis Thomas¹, C. Huttenhower¹, R. J. Xavier¹, J. S. Hyams¹, L. A. Denson² Sheba Medical Center, Tel Hashomer, Israel, Cincinnati Children Hospital Medical Center, Cincinnati, United States, Broad Institute of MIT and Harvard University, Cambridge, United States, Georgia Institute of Technology, Atlanta, United States, University of North Carolina, Chapel Hill, United States, Emory University, Atlanta, United States, Hospital For Sick Children, Toronto, Canada, Harvard School of Public Health, Boston, United States, Broad Institute of MIT and Harvard University, Boston, United States, Connecticut Children's Medical Center, Hartford, United States</p>
14:30-14:40	<p>39: OP20: Mucosal microRNA profiles predict response to autologous stem-cell transplantation in Crohn's Disease A. Lewis¹, R. Jeffrey², T. Kumagai³, C. J. Hawkey⁴, M. M. Clark⁵, M. Allez⁶, J. Satsangi¹, G. Rogler¹, A. Silver¹, J. O. Lindsay¹ Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Genomics and Child Health, London, United Kingdom, Centre for Digestive Diseases, Queens Medical Centre, Nottingham, United Kingdom, Department of Gastroenterology, Hôpital Saint Louis, APHP, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité University, Paris, France, Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, Department of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland, Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Immunobiology, London, United Kingdom</p>
14:40-15:10	Coffee break
ETHER:	
15:10-15:55	<p>Scientific session 7: ECCO Fellowships and Grants Edouard Lous, Liège, Belgium Janneke van der Woude, Rotterdam, The Netherlands</p>
15:10-15:17	<p>40: Outcomes of the ECCO Pioneer Award 2017: Faecal transplantation using a novel conditioning method for donor and recipient in mild to moderate treatment refractory colitis in Inflammatory Bowel Disease Arle Levine, Tel Aviv, Israel</p>
15:17-15:24	<p>41: Outcomes of the ECCO Fellowship 2018: Role of TNF-inducible gene-6 (TSG-6) in fistulising Crohn's Disease Sudharshan Elangovan, Thuwal, Saudi Arabia</p>

	15:24-15:31	42: Outcomes of the ECCO Fellowship 2018: Monocyte-derived macrophages as crucial players in the resolution of inflammation and tissue repair in Inflammatory Bowel Disease Sales Ibiza, Lisbon, Portugal
	15:31-15:38	43: Outcomes of the ECCO-IOIBD Fellowship 2017: Precision medicine for IBD using advanced machine learning Aria Zand, Los Angeles, United States
	15:38-15:45	44: Outcomes of the ECCO-IOIBD Fellowship 2018: Deciphering the gut-specific B cell response in Inflammatory Bowel Disease Mathieu Uzzan, Clichy, France
	15:45-15:55	45: Announcement of ECCO Fellowships and Grants 2019
15:55-16:55		Scientific session 8: IBD Horizons Dominik Bettenworth, Münster, Germany Janneke N. Samsom, Rotterdam, The Netherlands
	15:55-16:05	46: OP21: ABX464 is safe and efficacious in a proof of concept study in Ulcerative Colitis patients S. Vermeire ¹ , X. Hébuterne ² , P. Napora ³ , M. Wisniewska-Jarosinska ⁴ , G. Kiss ⁵ , A. Bourrelle ⁶ , Z. Przemyslaw ⁷ , J. Nitcheu ⁸ , P. Gineste ⁸ , J.-M. Steens ⁸ , H. Ehrlich ¹ ¹ University Hospitals Leuven, Leuven, Belgium, ² CHU Nice Hopital Archet 2, Nice, France, ³ Plotr Napora Centrum Badań Klinicznych Lekarze Sp.p., Wrocław, Poland, ⁴ SANTA FAMILIA, Centrum Badań, Profilaktyki i Leczenia, Łódź, Poland, ⁵ Vasútegészségügyi Nonprofit Közhasznú Kft, Debrecen, Hungary, ⁶ CHU Nantes Hotel Dieu, Nantes, France, ⁷ KO-Med, Lublin, Poland, ⁸ Abivax, Paris, France
	16:05-16:15	47: OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental Colitis M. Barnhoorn ¹ , L. Plug ¹ , E. Muller - de Jonge ¹ , E. Bos ¹ , A. van der Meulen - de Jong ¹ , H. Verspaget ¹ , L. Hawinkels ¹ ¹ Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, ² Leiden University Medical Center, Cell and Chemical Biology, Leiden, Netherlands
	16:15-16:25	48: OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates Colitis in various animal models J. Shin ¹ , N. Ha ¹ , D. Bae ² , D.-h. Suh ² , J.-y. Baek ³ , J. H. Jun ³ , Y. J. Lee ⁴ , Y. I. Choi ^{4,5} , K. H. Ryu ^{4,5} , G. S. Youn ⁴ , J. Park ⁴ , S.-M. Lee ⁴ , S.-k. Seo ⁴ , J. W. Lee ⁴ , J. S. Kim ¹ ¹ Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, South Korea, ² Hallym University, Department of Biomedical Science, Chuncheon, South Korea, ³ Inje University College of Medicine, Department of Microbiology and Immunology, Gimhae, South Korea, ⁴ Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, ⁵ Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine and Healthcare Research Institute, Seoul, South Korea
	16:25-16:35	49: OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's Disease M. Fumery ¹ , L. Peyrin-biroulet ² , S. Nancey ³ , R. Altwegg ⁴ , P. Veyrard ⁵ , G. Bouguen ⁶ , S. Viennot ⁷ , F. Poullenot ⁸ , J. Filippi ⁹ , A. Buisson ¹⁰ , A. Bozon ¹¹ , C. Gilletta ¹² , F. Brazier ¹³ , L. Pouillon ¹⁴ , B. Flourié ¹⁴ , L. Bolvineau ¹⁵ , L. Siproudhis ¹ , D. Laharie ¹ , X. Roblin ¹ , X. Treton ¹ ¹ Amlens University Hospital, Gastroenterology, AMIENS (80000), France, Nancy University Hospital, Gastroenterology, Nancy, France, ² Lyon University Hospital, Lyon, France, ³ Montpellier University Hospital, Gastroenterology, Montpellier, France, ⁴ Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France, ⁵ Rennes University Hospital, Gastroenterology, Rennes, France, ⁶ Caen University Hospital, Gastroenterology, Caen, France, ⁷ Bordeaux University Hospital, Gastroenterology, Bordeaux, France, ⁸ Nice University Hospital, Gastroenterology, Nice, France, ⁹ Clermont-Ferrand, Gastroenterology, Clermont Ferrand, France, ¹⁰ Hopital Beaujon, Gastroenterology, Clichy, France, ¹¹ Toulouse University Hospital, Gastroenterology, Toulouse, France, ¹² Amiens University Hospital, Gastroenterology, Amiens, France, ¹³ Lyon University Hospital, Gastroenterology, Lyon, France, ¹⁴ Saint Etienne University Hospital, Gastroenterology, Saint-Etienne, France

	16:35-16:45	<p>50: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's Disease</p> <p>¹ E. Dreesen , ² F. Baert , ³ D. Laharie , ⁴ P. Bossuyt , ⁵ Y. Bouhnik , ⁶ A. Bulsson , ⁷ G. Lambrecht , ⁸ E. Louls , ⁹ B. Oldenburg , ¹⁰ B. Pariente , ¹¹ M. Pierik , ¹² C. J. van der Woude , ¹³ G. D'Haens , ¹⁴ S. Vermeire , ¹⁵ A. Gils</p> <p>¹ University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ² AZ Delta, Department of Gastroenterology, Roeselare, Belgium, ³ Hôpital Haut-Lévêque, Service d'Hépatogastroentérologie et Oncologie Digestive, Bordeaux, France, ⁴ Imelda General Hospital, IBD Clinic, Bonheiden, Belgium, ⁵ Beaujon Hospital, APHP, Paris Diderot University, ⁶ Department of Gastroenterology, Clichy, France, ⁷ Estaing University Hospital, ⁸ Department of Gastroenterology, Clermont-Ferrand, France, ⁹ AZ Damiaan, ¹⁰ Department of Gastroenterology, Oostende, Belgium, ¹¹ Liège University Hospital, ¹² Department of Gastroenterology, Liège, Belgium, ¹³ University Medical Centre, ¹⁴ Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ¹⁵ Huriez Hospital, Lille 2 University, Department of Gastroenterology and Hepatology, Lille, France, ¹⁶ University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ¹⁷ Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ¹⁸ Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, ¹⁹ University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²⁰ University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium</p>
	16:45-16:55	<p>51: OP26: Long-term safety of vedolizumab in Ulcerative Colitis and Crohn's Disease: Final results from the GEMINI LTS study</p> <p>¹ S. Vermeire , ² J.-F. Colombel , ³ B. G. Feagan , ⁴ W. J. Sandborn , ⁵ B. E. Sands , ⁶ S. Danese , ⁷ G. D'Haens , ⁸ R. Panaccione , ⁹ D. T. Rubin , ¹⁰ I. Shafran , ¹¹ A. Parfonovas , ¹² R. Rogers , ¹³ R. A. Lirio , ¹⁴ E. V. Loftus, Jr</p> <p>¹ University Hospitals Leuven, Leuven, Belgium, ² Icahn School of Medicine at Mount Sinai, New York, United States, ³ Western University, London, Canada, ⁴ University of California San Diego, La Jolla, United States, ⁵ Humanitas University, Milan, Italy, ⁶ Academic Medical Centre, Amsterdam, Netherlands, ⁷ University of Calgary, Calgary, Canada, ⁸ University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States, ⁹ Shafran Gastroenterology Research Center, Winter Park, United States, ¹⁰ Takeda Pharmaceuticals, Cambridge, United States, ¹¹ Mayo Clinic College of Medicine, Rochester, United States</p>
OR:		
15:10-16:50	<p>Scientific session 9: Basic Science: Immune cells and microbes: A happy marriage?</p> <p>Tim Raine, Cambridge, United Kingdom</p> <p>Raja Atreya, Erlangen, Germany</p>	
	15:10-15:30	<p>52: Metabolic profiling - the new player in microbiome research</p> <p>Stefan Schreiber, Kiel, Germany</p>
	15:30-15:40	<p>53: OP27: High-dimensional mass cytometry reveals the immune cell landscape in Inflammatory Bowel Disease</p> <p>¹ V. van Unen , ² N. Li , ³ T. Abdelal , ⁴ Y. Kooy-Winkelaar , ⁵ L. Ouboter , ⁶ G. Beyrend , ⁷ T. Höllt , ⁸ L. Mearin , ⁹ A. Witte , ¹⁰ H. Escher , ¹¹ B. Lelieveldt , ¹² A. van der Meulen - de Jong , ¹³ F. Koning</p> <p>¹ Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, Netherlands, ² Delft University of Technology, Delft ³ Bioinformatics Lab, Delft, Netherlands, ⁴ Leiden University Medical Center, Leiden ⁵ Computational Biology Center, Leiden, Netherlands, ⁶ Leiden University Medical Center, Department of Gastroenterology, Leiden, Netherlands, ⁷ Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, ⁸ Delft University of Technology, Computer Graphics and Visualization, Delft, Netherlands, ⁹ Leiden University Medical Center, Department of Paediatrics, Leiden, Netherlands, ¹⁰ Alrijne Hospital, Department of Gastroenterology, Leiderdorp, Netherlands, ¹¹ Erasmus University Medical Center, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ¹² Delft University of Technology, Pattern Recognition and Bioinformatics Group, Delft, Netherlands, ¹³ Leiden University Medical Center, Department of LKEB Radiology, Leiden, Netherlands</p>

		<p>54: OP28: Host-microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis M. Neyazi¹, N. Hott², Oxford IBD Cohort study Investigators¹, S. Travis¹, C. Arancibia¹, F. Powrie², A. Geremia¹</p>	
<p>Contact us European Crohn's and Colitis Organisation Ungargasse 6/13, A-1030 Vienna, Austria Tel: +43-(0)1-710 2242-0 Fax: +43-(0)1-710 2242-001 E-Mail: ecco@ecco-ibd.eu (mailto:ecco@ecco-ibd.eu)</p>	<p>15:40-15:50</p>	<p>University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom</p>	
<p>HOME (/DISCOVER-THE-PROGRAMME-2019/SCIENTIFIC-PROGRAMME-2019.HTML) (/CONTACT45.HTML) (/DATA-PRIVACY-STATEMENT)</p>		<p>55: Using mucosal immune pathways to predict disease outcome Ahmed Hegazy, Berlin, Germany</p>	<p>IMPRINT (/IMPRINT.HTML)</p>
<p>© ECCO 2018 All rights reserved.</p>		<p>56: OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer L. R. Lopetuso¹, C. De Salvo², L. Di Martino², W. Goodman², F. Scalfaferrì³, A. Armuzzi¹, A. Gasbarrini¹, T. T. Pizarro¹</p>	
	<p>16:10-16:20</p>	<p>Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrinology-Metabolical Sciences Department, Roma, Italy, Case Western Reserve University, Cleveland, United States, Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrinology-Metabolical Sciences Department, Roma, Italy</p>	
	<p>16:20-16:30</p>	<p>57: OP30: Serum proteomic profiling predicts and diagnoses pouchitis in Ulcerative Colitis patients undergoing ileal pouch-anal anastomosis K. Machiels¹, M. Ferrante^{1,2}, N. Davani¹, A. Wolthuis³, A. D'Hoore³, S. Vermeire¹ KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, University Hospitals Leuven, Department of gastroenterology and hepatology, Leuven, Belgium, University Hospitals Leuven, Abdominal surgery, Leuven, Belgium</p>	
	<p>16:30-16:50</p>	<p>58: Resolution pathways: Next frontier to control intestinal inflammation Silvia D'Alessio, Milan, Italy</p>	
<p>17:20-18:20</p>		<p>Digital Oral Presentations Sessions 6-10</p>	
<p>18:35-19:35</p>		<p>Industry sponsored satellite symposia 4a, 4b, 4c, & 4d</p>	